RAD-140 vs Ostarine: Understanding Design and Development
RAD-140 (Testolone) and Ostarine (MK-2866) are both known as Selective Androgen Receptor Modulators (SARMs). Despite their similarities, they have distinct paths in terms of clinical trial progress and development.
What Was RAD-140 Designed To Do?
RAD-140, created by Radius Health, remains in the preclinical research phase. It is aimed at addressing muscle wasting while also offering potential neuroprotective benefits. This compound is engineered to selectively target androgen receptors in muscle and brain tissues, minimizing the side effects commonly associated with traditional anabolic steroids.
What Was Ostarine Designed To Do?
Ostarine, developed by GTx, Inc., has progressed through numerous human clinical trials. It is designed to treat muscle wasting and cachexia, a condition marked by weight loss and muscle degeneration. The availability of human clinical data for Ostarine provides significant insights into its efficacy and safety, distinguishing it from RAD-140, which lacks such comprehensive data.
Key Differences
| Aspect | RAD-140 | Ostarine |
|---|---|---|
| Developer | Radius Health | GTx, Inc. |
| Research Stage | Preclinical | Multiple human trials |
| Human Data | None | Available |
| Development Trajectory | Focused on preclinical research | Advanced with clinical trial data |
What Actually Separates Them?
The primary distinction between RAD-140 and Ostarine lies in their clinical trial histories. Ostarine benefits from extensive human trial data that highlights its effects and safety profile. In contrast, RAD-140 is still in the preclinical stage, with no human trial data available yet.
Legal + Disclaimer
Both RAD-140 and Ostarine are research compounds, and their use must adhere to local legal regulations. This content is for educational purposes only and is not intended as medical advice.